Eliminating lymphatic filariasis: a view from the field.
Identifieur interne : 003227 ( PubMed/Curation ); précédent : 003226; suivant : 003228Eliminating lymphatic filariasis: a view from the field.
Auteurs : Thomas Streit [États-Unis] ; Jack Guy LafontantSource :
- Annals of the New York Academy of Sciences [ 0077-8923 ] ; 2008.
Descripteurs français
- KwdFr :
- MESH :
- diagnostic : Filariose lymphatique.
- ressources et distribution : Préparations pharmaceutiques.
- traitement médicamenteux : Filariose lymphatique.
- économie : Filariose lymphatique.
- épidémiologie : Filariose lymphatique.
- Filariose lymphatique, Haïti, Humains, Pauvreté, Rôle, Science.
- Wicri :
- geographic : Haïti.
English descriptors
- KwdEn :
- MESH :
- chemical , supply & distribution : Pharmaceutical Preparations.
- geographic : Haiti.
- diagnosis : Elephantiasis, Filarial.
- drug therapy : Elephantiasis, Filarial.
- economics : Elephantiasis, Filarial.
- epidemiology : Elephantiasis, Filarial.
- prevention & control : Elephantiasis, Filarial.
- Humans, Poverty, Role, Science.
Abstract
Among infections closely associated with poverty, lymphatic filariasis (LF) is a study in contrasts. It is both a consequence of and a contributor to poverty. Although rarely fatal, it is recognized as a leading global cause of lifelong disability as well as significant personal, social, and economic burdens coincident with disease. Infection is often considerably more prevalent in communities than the number of cases of overt pathology for which LF is best known (lymphedema, elephantiasis, and hydrocele). With an estimated 120 million to 130 million affected persons in 83 countries and 1.25 billion persons living in areas at risk, in some countries LF may be expanding its range, whereas in others, with economic development, it has disappeared with little if any targeted intervention. The transmission cycle is relatively inefficient, yet an association with pockets of deepest poverty remains tenacious. Thanks to scientific advances in diagnostic tools, and particularly in control strategies focused on large-scale drug donation and mass drug distribution programs, scientists and policy makers now consider LF eliminable. Together with new approaches for morbidity control, a hopeful tone surrounds a disease problem that as recently as two decades ago could easily have been categorized as among the most neglected of neglected diseases. Continued progress toward global LF elimination will require solutions to potential obstacles in the most challenging--that is, the poorest--endemic settings. This chapter reviews progress toward LF elimination and some of the remaining challenges from a perspective in Haiti, the only least developed country of the Americas.
DOI: 10.1196/annals.1425.036
PubMed: 18579875
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :003227
Links to Exploration step
pubmed:18579875Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Eliminating lymphatic filariasis: a view from the field.</title><author><name sortKey="Streit, Thomas" sort="Streit, Thomas" uniqKey="Streit T" first="Thomas" last="Streit">Thomas Streit</name><affiliation wicri:level="1"><nlm:affiliation>Center for Global Health and Infectious Diseases, Department of Biological Sciences, University of Notre Dame, Notre Dame, IN 46556-0369, USA. tstreit@nd.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Global Health and Infectious Diseases, Department of Biological Sciences, University of Notre Dame, Notre Dame, IN 46556-0369</wicri:regionArea></affiliation></author><author><name sortKey="Lafontant, Jack Guy" sort="Lafontant, Jack Guy" uniqKey="Lafontant J" first="Jack Guy" last="Lafontant">Jack Guy Lafontant</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2008">2008</date><idno type="RBID">pubmed:18579875</idno><idno type="pmid">18579875</idno><idno type="doi">10.1196/annals.1425.036</idno><idno type="wicri:Area/PubMed/Corpus">003227</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003227</idno><idno type="wicri:Area/PubMed/Curation">003227</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">003227</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Eliminating lymphatic filariasis: a view from the field.</title><author><name sortKey="Streit, Thomas" sort="Streit, Thomas" uniqKey="Streit T" first="Thomas" last="Streit">Thomas Streit</name><affiliation wicri:level="1"><nlm:affiliation>Center for Global Health and Infectious Diseases, Department of Biological Sciences, University of Notre Dame, Notre Dame, IN 46556-0369, USA. tstreit@nd.edu</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Center for Global Health and Infectious Diseases, Department of Biological Sciences, University of Notre Dame, Notre Dame, IN 46556-0369</wicri:regionArea></affiliation></author><author><name sortKey="Lafontant, Jack Guy" sort="Lafontant, Jack Guy" uniqKey="Lafontant J" first="Jack Guy" last="Lafontant">Jack Guy Lafontant</name></author></analytic><series><title level="j">Annals of the New York Academy of Sciences</title><idno type="ISSN">0077-8923</idno><imprint><date when="2008" type="published">2008</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Elephantiasis, Filarial (diagnosis)</term><term>Elephantiasis, Filarial (drug therapy)</term><term>Elephantiasis, Filarial (economics)</term><term>Elephantiasis, Filarial (epidemiology)</term><term>Elephantiasis, Filarial (prevention & control)</term><term>Haiti</term><term>Humans</term><term>Pharmaceutical Preparations (supply & distribution)</term><term>Poverty</term><term>Role</term><term>Science</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Filariose lymphatique ()</term><term>Filariose lymphatique (diagnostic)</term><term>Filariose lymphatique (traitement médicamenteux)</term><term>Filariose lymphatique (économie)</term><term>Filariose lymphatique (épidémiologie)</term><term>Haïti</term><term>Humains</term><term>Pauvreté</term><term>Préparations pharmaceutiques (ressources et distribution)</term><term>Rôle</term><term>Science</term></keywords><keywords scheme="MESH" type="chemical" qualifier="supply & distribution" xml:lang="en"><term>Pharmaceutical Preparations</term></keywords><keywords scheme="MESH" type="geographic" xml:lang="en"><term>Haiti</term></keywords><keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="diagnostic" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="economics" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="epidemiology" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="prevention & control" xml:lang="en"><term>Elephantiasis, Filarial</term></keywords><keywords scheme="MESH" qualifier="ressources et distribution" xml:lang="fr"><term>Préparations pharmaceutiques</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" qualifier="économie" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr"><term>Filariose lymphatique</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Poverty</term><term>Role</term><term>Science</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Filariose lymphatique</term><term>Haïti</term><term>Humains</term><term>Pauvreté</term><term>Rôle</term><term>Science</term></keywords><keywords scheme="Wicri" type="geographic" xml:lang="fr"><term>Haïti</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Among infections closely associated with poverty, lymphatic filariasis (LF) is a study in contrasts. It is both a consequence of and a contributor to poverty. Although rarely fatal, it is recognized as a leading global cause of lifelong disability as well as significant personal, social, and economic burdens coincident with disease. Infection is often considerably more prevalent in communities than the number of cases of overt pathology for which LF is best known (lymphedema, elephantiasis, and hydrocele). With an estimated 120 million to 130 million affected persons in 83 countries and 1.25 billion persons living in areas at risk, in some countries LF may be expanding its range, whereas in others, with economic development, it has disappeared with little if any targeted intervention. The transmission cycle is relatively inefficient, yet an association with pockets of deepest poverty remains tenacious. Thanks to scientific advances in diagnostic tools, and particularly in control strategies focused on large-scale drug donation and mass drug distribution programs, scientists and policy makers now consider LF eliminable. Together with new approaches for morbidity control, a hopeful tone surrounds a disease problem that as recently as two decades ago could easily have been categorized as among the most neglected of neglected diseases. Continued progress toward global LF elimination will require solutions to potential obstacles in the most challenging--that is, the poorest--endemic settings. This chapter reviews progress toward LF elimination and some of the remaining challenges from a perspective in Haiti, the only least developed country of the Americas.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">18579875</PMID><DateCreated><Year>2008</Year><Month>06</Month><Day>26</Day></DateCreated><DateCompleted><Year>2008</Year><Month>08</Month><Day>14</Day></DateCompleted><DateRevised><Year>2008</Year><Month>06</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">0077-8923</ISSN><JournalIssue CitedMedium="Print"><Volume>1136</Volume><PubDate><Year>2008</Year></PubDate></JournalIssue><Title>Annals of the New York Academy of Sciences</Title><ISOAbbreviation>Ann. N. Y. Acad. Sci.</ISOAbbreviation></Journal><ArticleTitle>Eliminating lymphatic filariasis: a view from the field.</ArticleTitle><Pagination><MedlinePgn>53-63</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1196/annals.1425.036</ELocationID><Abstract><AbstractText>Among infections closely associated with poverty, lymphatic filariasis (LF) is a study in contrasts. It is both a consequence of and a contributor to poverty. Although rarely fatal, it is recognized as a leading global cause of lifelong disability as well as significant personal, social, and economic burdens coincident with disease. Infection is often considerably more prevalent in communities than the number of cases of overt pathology for which LF is best known (lymphedema, elephantiasis, and hydrocele). With an estimated 120 million to 130 million affected persons in 83 countries and 1.25 billion persons living in areas at risk, in some countries LF may be expanding its range, whereas in others, with economic development, it has disappeared with little if any targeted intervention. The transmission cycle is relatively inefficient, yet an association with pockets of deepest poverty remains tenacious. Thanks to scientific advances in diagnostic tools, and particularly in control strategies focused on large-scale drug donation and mass drug distribution programs, scientists and policy makers now consider LF eliminable. Together with new approaches for morbidity control, a hopeful tone surrounds a disease problem that as recently as two decades ago could easily have been categorized as among the most neglected of neglected diseases. Continued progress toward global LF elimination will require solutions to potential obstacles in the most challenging--that is, the poorest--endemic settings. This chapter reviews progress toward LF elimination and some of the remaining challenges from a perspective in Haiti, the only least developed country of the Americas.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Streit</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Center for Global Health and Infectious Diseases, Department of Biological Sciences, University of Notre Dame, Notre Dame, IN 46556-0369, USA. tstreit@nd.edu</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lafontant</LastName><ForeName>Jack Guy</ForeName><Initials>JG</Initials></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Ann N Y Acad Sci</MedlineTA><NlmUniqueID>7506858</NlmUniqueID><ISSNLinking>0077-8923</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004364">Pharmaceutical Preparations</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D004605" MajorTopicYN="N">Elephantiasis, Filarial</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000191" MajorTopicYN="N">economics</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000517" MajorTopicYN="Y">prevention & control</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006205" MajorTopicYN="N" Type="Geographic">Haiti</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004364" MajorTopicYN="N">Pharmaceutical Preparations</DescriptorName><QualifierName UI="Q000600" MajorTopicYN="N">supply & distribution</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011203" MajorTopicYN="Y">Poverty</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012380" MajorTopicYN="N">Role</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012586" MajorTopicYN="N">Science</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2008</Year><Month>6</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2008</Year><Month>8</Month><Day>15</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2008</Year><Month>6</Month><Day>27</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">18579875</ArticleId><ArticleId IdType="pii">1136/1/53</ArticleId><ArticleId IdType="doi">10.1196/annals.1425.036</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/LymphedemaV1/Data/PubMed/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003227 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd -nk 003227 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= LymphedemaV1
|flux= PubMed
|étape= Curation
|type= RBID
|clé= pubmed:18579875
|texte= Eliminating lymphatic filariasis: a view from the field.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Curation/RBID.i -Sk "pubmed:18579875" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Curation/biblio.hfd \
| NlmPubMed2Wicri -a LymphedemaV1
| This area was generated with Dilib version V0.6.31. |  |